Get started

NURO

NURO | Time to Enter | LONGNeuroMetrix, Inc., a healthcare company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, China, the Middle East, and Mexico. Its primary marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system, a platform for the performance of nerve conduction studies. The company offers its products to managed care organizations, endocrinologists, podiatrists, and primary care physicians; occupational health, primary care, internal medicine, orthopedic, and hand surgeons; and pain medicine physicians, neurologists, physical medicine and rehabilitation physicians, and neurosurgeons. NeuroMetrix, Inc. was incorporated in 1996 and is headquartered in Woburn, Massachusetts.
NASDAQ:NUROLong
by DivergenceSeeker
ROKU - FOLLOW THE PARABOLIC ARCAll, Pretty bullish on ROKU here. Only question right now is that if SPY holds since it had a tear back up from 420s. However, this looks like its ready to go might retrace some here so mayh want to wait for a better entry. Just watch closely. I think as long as market doesn't cause a crash in big stocks like ROKU we see 440s and probably 480s. IF THIS BREAKS THE PARABLOIC ARC... the right side it will fall and I would take a PUT or short position
NASDAQ:ROKULong
by DigitalData
NURO Update Part 2Updating on day 2 of this NURO run as premarket highs have it making new multi-year highs. Looks like that highest-high fib line ( around 18.90) could be sticky as it was a failure point in 2018 and a heavy traffic area in 2017, which was support at that time. Let's see what happens here and whether the 17.70-17.80 area will hold as resistance or if there's enough gas left in the tank. I took the NURO chart out to 2019, which was the last time it traded around these levels. After plotting these fibs, wouldn't you know, the 236 and 382 lined up almost EXACTLY with today's action. The 382 could be an important level to watch as this was a prior area of "high traffic" and a support/resistance pivot in 2019. With volume surging, 382 fib line could be a key level t pay attention to. **The big spike in trading action on July 20th stemmed from FDA news. NeuroMetrix announced that it received FDA Breakthrough Device Designation for treating fibromyalgia. Specifically, its Quell device garnered the interest of the stock market today. The device is non-invasive and is a nerve stimulator covered by 18 U.S. utility patents already. This Breakthrough Device Program aims to help patients gain quicker access to technologies like Quell that could provide more effective treatments. “We are moving forward with a regulatory filing that could position us to launch Quell for this indication in the second half of next year.” Shai N. Gozani, M.D., Ph .D., President and CEO of NeuroMetrix Later this week, the company releases its Q2 results. So if NURO stock is on your list right now, keep July 22nd in mind. The company will also host a conference call before the market opens on that day. Read More On NeuroMetrix .** Quote Source: 4 Penny Stocks To Watch As Hedge Against Dogecoin Price Drop Today
NASDAQ:NURO
by PennyStocks101
NURO Fibbing Right Now Or New Highs Next?I took the NURO chart out to 2019, which was the last time it traded around these levels. After plotting these fibs, wouldn't you know, the 236 and 382 lined up almost EXACTLY with today's action. The 382 could be an important level to watch as this was a prior area of "high traffic" and a support/resistance pivot in 2019. With volume surging, 382 fib line could be a key level t pay attention to. **The big spike in trading action on July 20th stemmed from FDA news. NeuroMetrix announced that it received FDA Breakthrough Device Designation for treating fibromyalgia. Specifically, its Quell device garnered the interest of the stock market today. The device is non-invasive and is a nerve stimulator covered by 18 U.S. utility patents already. This Breakthrough Device Program aims to help patients gain quicker access to technologies like Quell that could provide more effective treatments. “We are moving forward with a regulatory filing that could position us to launch Quell for this indication in the second half of next year.” Shai N. Gozani, M.D., Ph.D., President and CEO of NeuroMetrix Later this week, the company releases its Q2 results. So if NURO stock is on your list right now, keep July 22nd in mind. The company will also host a conference call before the market opens on that day. Read More On NeuroMetrix .** Quote Source: 4 Penny Stocks To Watch As Hedge Against Dogecoin Price Drop Today
NASDAQ:NURO
by PennyStocks101
NeuroMetrix, Inc, Low Float, Lands Deal With GlaxoSmithKlineNew and innovative product. Quell's proven technology is 5x more powerful on average than other over-the-counter pain relief devices. It is discreet and completely wearable to enable pain relief when your patients need it. Increased quarterly earnings growth. Low floater Resistance at at 3.00 range due to the preferred shares being exercisible at 2.83 Target is 2.50. Nice day trade potential. They just had the biggest trading volume in a very long time, by a long shot.
NASDAQ:NURO
by alipipefitter
1